Risk and Prognosis of Upper Extremity Deep Vein Thrombosis

被引：1

作者：

Endo, Yusuke ^{[1
,2
]}

Unno, Naoki ^{[1
,2
,3
]}

Yamamoto, Naoto ^{[3
]}

Sano, Masaki ^{[1
,2
]}

Katahashi, Kazuto ^{[1
,2
]}

Kayama, Takafumi ^{[1
,2
]}

Yamanaka, Yuta ^{[1
,2
]}

Tsuyuki, Hajime ^{[1
,2
]}

Takeuchi, Hiroya ^{[2
]}

Inuzuka, Kazunori ^{[1
,2
,4
]}

机构：

[1] Hamamatsu Univ Sch Med, Div Vasc Surg, Hamamatsu, Shizuoka, Japan

[2] Hamamatsu Univ Sch Med, Dept Surg 2, Hamamatsu, Shizuoka, Japan

[3] Hamamatsu Med Ctr, Dept Vasc Surg, Hamamatsu, Shizuoka, Japan

[4] Hamamatsu Univ Sch Med, 1-20-1 Handayama,Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan

来源：

ANNALS OF VASCULAR DISEASES | 2023年 / 16卷 / 03期

关键词：

upper extremity deep vein thrombosis; pulmo; nant tumor; mortality; MANAGEMENT;

D O I：

10.3400/avd.oa.23-00005

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Objectives: We aimed to investigate the clinical features of Methods: We retrospectively reviewed the background, thrombus site, treatment, and outcome of 76 UEDVT patients. Results: Of the 76 UEDVT patients, 44 (57.9%) were men, and 51 (67.1%) were complicated by malignancy, 44 (57.9%) had an indwelling central vein (CV) catheter, 8 (10.5%) had concomitant pulmonary embolization (PE), and 33 (43.3%) were symptomatic. Regarding the thrombus site, the right internal jugular vein was the most common, with 30 cases (35.3%). As regards the treatment method, 53 patients (69.7%) received oral anticoagulants. In 2015, when direct oral anticoagulants (DOACs) was covered by insurance, there were 44 UEDVT cases, of which 34 (77.3%) received DOACs. Outcomes at a mean observation period of 37.5 +/- 41.5 months included 40 deaths (52.6%) with a mean survival of 16.3 +/- 21.3 months. The most common cause of death was malignancy, with 33 cases (82.5%). Conclusion: In the background of UEDVT, the combination of indwelling CV catheter placement and malignancy was frequently observed. While the risk of recurrence or PE complications is low, the prognosis of UEDVT complicated by malignancy is extremely poor.

引用

页码：200 / 204

页数：5

共 20 条

[11] The Risk Factors and Clinical Outcomes of Upper Extremity Deep Vein Thrombosis [J].

Lee, Jung-Ah ;

Zierler, Brenda K. ;

Zierler, R. Eugene .

VASCULAR AND ENDOVASCULAR SURGERY, 2012, 46 (02) :139-144

[12] Upper extremity deep vein thrombosis: The oft-forgotten cousin of venous thromboembolic disease [J].

Margey R. ;

Schainfeld R.M. .

Current Treatment Options in Cardiovascular Medicine, 2011, 13 (2) :146-158

[13]

Prandoni P, 1999, Curr Opin Pulm Med, V5, P222, DOI 10.1097/00063198-199907000-00008

[14] Characterization and probability of upper extremity deep venous thrombosis [J].

Schmittling, ZC ;

McLafferty, RB ;

Bohannon, WT ;

Ramsey, DE ;

Hodgson, KJ .

ANNALS OF VASCULAR SURGERY, 2004, 18 (05) :552-557

[15] Methodology for antithrombotic and thrombolytic therapy guideline development [J].

Schunemann, Holger J. ;

Cook, Deborah ;

Guyatt, Gordon .

CHEST, 2008, 133 (06) :113S-122S

[16] Upper-extremity deep vein thrombosis [J].

Shah, MK ;

Burke, DT ;

Shah, SH .

SOUTHERN MEDICAL JOURNAL, 2003, 96 (07) :669-672

[17] Upper extremity deep vein thrombosis: A community-based perspective [J].

Spencer, Frederick A. ;

Emery, Cathy ;

Lessard, Darleen ;

Goldberg, Robert J. .

AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) :678-U1

[18] Upper extremity deep vein thrombosis [J].

Spiezia, Luca ;

Simioni, Paolo .

INTERNAL AND EMERGENCY MEDICINE, 2010, 5 (02) :103-109

[19]

Uchida N, 2019, Jpn J Phlebol, V30, P305

[20] Upper extremities deep vein thrombosis treated with oral direct anticoagulants: A prospective cohort study [J].

Vedovati, Maria Cristina ;

Tratar, Gregor ;

Mavri, Alenka ;

Mazzetti, Matteo ;

Rosa, Vladimir Salazar ;

Pierpaoli, Lucia ;

Cotugno, Marilena ;

Agnelli, Giancarlo ;

Becattini, Cecilia .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 339 :158-163

← 1 2 →